Rentokil shares jump 8% as $200 million buyback and steady third quarter reassure investors

Impact · against what's priced in

Rentokil's share buyback and organic growth provide a tactical catalyst, while the news confirms the continued weakness at Rollins. For Rollins, the confirmation of disappointing third-quarter performance reinforces the current bearish pricing of its growth trajectory.

ROL−0.10

Already priced in

The price assumes

Organic revenue growth of roughly 6%, matching the company's revised downward forecast.